Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Tuesday, August 23, 2016

History of stroke may increase risk for late-onset Alzheimer’s disease

So, What the fuck is your doctor doing to prevent that from happening to you?
Throwing their hands up is not an acceptable answer. Screaming in their faces is an acceptable reply from you. YOU have to put the monkey on their back and never let them transfer it back to you. Tell them you know all about the Harvard Business Review article on monkey on the back tossing.

History of stroke may increase risk for late-onset Alzheimer’s disease

Patients with a history of stroke have double the risk for late-onset Alzheimer’s disease in its familial and sporadic forms, researchers reported in JAMA Neurology.
However, according to the researchers, the effect of CV risk factors on Alzheimer’s disease was mediated by stroke.
Using data from the National Institute on Aging Late-Onset Alzheimer’s Disease/National Cell Repository for Alzheimer’s Disease family study (NIA-LOAD), the researchers assessed the contribution of CV risk factors and history of stroke to late-onset Alzheimer’s disease in large families with multiple family members affected by late-onset Alzheimer’s disease. Data from the Washington Heights-Inwood Columbia Aging Project were used to replicate findings.
The primary endpoint was probable or possible late-onset Alzheimer’s disease based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria. The CV risk factors included in the study were hypertension, type 2 diabetes and CHD.
Giuseppe Tosto, MD, PhD, from Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, and colleagues calculated a genetic risk score for late-onset Alzheimer’s disease using genome-wide significant single nucleotide polymorphisms except for APOE E4.
Of the 6,553 participants (mean age, 77 years; 62% women) included in the analyses from NIA-LOAD, 3,468 were diagnosed with late-onset Alzheimer’s disease. Of the 5,972 participants (mean age, 77 years; 68% women) in the replication sample, 2,684 had late-onset Alzheimer’s disease.
In the NIA-LOAD analysis, hypertension was associated with a lower risk for late-onset Alzheimer’s disease (OR = 0.63; 95% CI, 0.55-0.72), whereas a history of stroke was associated with twice the risk for late-onset Alzheimer’s disease (OR = 2.23; 95% CI, 1.75-2.83). No associations were observed between late-onset Alzheimer’s disease and type 2 diabetes or CHD.
In the replication study, hypertension did not have an association with late-onset Alzheimer’s disease, nor did any of the other CV risk factors. However, a relationship was again found between late-onset Alzheimer’s disease and history of stroke (OR = 1.96; 95% CI, 1.56-2.46).
According to the researchers, these results highlight the “complex relationship between hypertension and [late-onset Alzheimer’s disease]” as well as the “importance of interventions targeting modifiable risk factors in [late-onset Alzheimer’s disease]. Further studies with longitudinal assessment and a larger set of variables (eg, different classes of treatments) are currently needed.” by Tracey Romero
Disclosure: Tosto reports no relevant financial disclosures. Please see the full study for a list of all other researchers’ relevant financial disclosures.

No comments:

Post a Comment